Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study.
Wang-Gillam A, Lim KH, McWilliams R, Suresh R, Lockhart AC, Brown A, Breden M, Belle JI, Herndon J, Bogner SJ, Pedersen K, Tan B, Boice N, Acharya A, Abdiannia M, Gao F, Yoon HH, Zhu M, Trikalinos NA, Ratner L, Aranha O, Hawkins WG, Herzog BH, DeNardo DG.
Wang-Gillam A, et al. Among authors: boice n.
Clin Cancer Res. 2022 Dec 15;28(24):5254-5262. doi: 10.1158/1078-0432.CCR-22-0308.
Clin Cancer Res. 2022.
PMID: 36228156
Free PMC article.
Clinical Trial.